EMEA-002342-PIP02-18
Key facts
| Invented name |
Verzenios
|
| Active substance |
abemaciclib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0021/2020
|
| PIP number |
EMEA-002342-PIP02-18
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
|
| Contact for public enquiries |
Eli Lilly and Company Limited (US)
Tel.: +1 31 75448941 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|